Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.
Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K, Campa D, Aftab B, Bracci P, Buda G, Zhao Y, Caswell-Jin J, Diasio R, Dumontet C, Dudziński M, Fejerman L, Greenberg A, Huntsman S, Jamroziak K, Jurczyszyn A, Kumar S, Atanackovic D, Glenn M, Cannon-Albright LA, Jones B, Lee A, Marques H, Martin T, Martinez-Lopez J, Rajkumar V, Sainz J, Vangsted AJ, Wątek M, Wolf J, Slager S, Camp NJ, Canzian F, Vachon C. Ziv E, et al. Among authors: buda g. Nat Commun. 2015 Jul 22;6:7539. doi: 10.1038/ncomms8539. Nat Commun. 2015. PMID: 26198393 Free PMC article.
MDR1 polymorphism influences the outcome of multiple myeloma patients.
Buda G, Maggini V, Galimberti S, Martino A, Giuliani N, Morabito F, Genestreti G, Iacopino P, Rizzoli V, Barale R, Rossi AM, Petrini M. Buda G, et al. Br J Haematol. 2007 Jun;137(5):454-6. doi: 10.1111/j.1365-2141.2007.06605.x. Br J Haematol. 2007. PMID: 17488488 Free article.
MDR1 diplotypes as prognostic markers in multiple myeloma.
Maggini V, Buda G, Martino A, Presciuttini S, Galimberti S, Orciuolo E, Barale R, Petrini M, Rossi AM. Maggini V, et al. Among authors: buda g. Pharmacogenet Genomics. 2008 May;18(5):383-9. doi: 10.1097/FPC.0b013e3282f82297. Pharmacogenet Genomics. 2008. PMID: 18408561
Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.
Buda G, Ricci D, Huang CC, Favis R, Cohen N, Zhuang SH, Harousseau JL, Sonneveld P, Bladé J, Orlowski RZ. Buda G, et al. Ann Hematol. 2010 Nov;89(11):1133-40. doi: 10.1007/s00277-010-0992-3. Epub 2010 Jun 8. Ann Hematol. 2010. PMID: 20532504 Free PMC article.
Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review).
Martino A, Sainz J, Buda G, Jamroziak K, Reis RM, García-Sanz R, Jurado M, Ríos R, Szemraj-Rogucka Z, Marques H, Lesueur F, Moreno V, Orciuolo E, Gemignani F, Landi S, Rossi AM, Dumontet C, Petrini M, Campa D, Canzian F. Martino A, et al. Among authors: buda g. Int J Oncol. 2012 Mar;40(3):625-38. doi: 10.3892/ijo.2011.1284. Epub 2011 Dec 6. Int J Oncol. 2012. PMID: 22159523 Free article. Review.
Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case-control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium.
Martino A, Campa D, Buda G, Sainz J, García-Sanz R, Jamroziak K, Reis RM, Weinhold N, Jurado M, Ríos R, Szemraj-Rogucka Z, Marques H, Szemraj J, Stein A, Kumar R, Orciuolo E, Gemignani F, Landi S, Goldschmidt H, Petrini M, Dumontet C, Canzian F, Rossi AM. Martino A, et al. Among authors: buda g. Leukemia. 2012 Jun;26(6):1419-22. doi: 10.1038/leu.2011.352. Epub 2011 Dec 20. Leukemia. 2012. PMID: 22182917 No abstract available.
153 results